Advertisement

Topics

GSK Launches Up-to-$43M AI-Focused Collaboration with Exscientia

06:38 EDT 5 Jul 2017 | Genetic Engineering News

GlaxoSmithKline (GSK) will use the artificial intelligence-enabled platform of Exscientia to develop new drugs, through a collaboration that could generate up to £33 million ($43 million) in milestone payments for the British AI-focused drug discovery and design company. GSK said it will use Exscientia’s platform to discover novel and selective small molecules for up to 10 disease-related targets, to be chosen by GSK across “multiple” therapeutic areas. Exscientia plans to apply big-data resources—from its medicinal chemistry and large-scale bio-assays, to its AI-driven algorithms—to design novel molecules with a single target each. Exscientia said it will receive research payments from GSK toward new discovery programs with nominated targets, with the goal of delivering pre-clinical candidates. Exscientia is also eligible for near-term payments tied to achieving lead and pre-clinical candidate milestones. If candidates for all 10 envisioned targets are advanced, Exscientia added, it will receive the £33 million ...

Original Article: GSK Launches Up-to-$43M AI-Focused Collaboration with Exscientia

NEXT ARTICLE

More From BioPortfolio on "GSK Launches Up-to-$43M AI-Focused Collaboration with Exscientia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...